SCHEMBL25748552

SCHEMBL25748552

COc1ccc2[nH]cc(CCN(C)C(C)C)c2c1F

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 9/20 0.77
HTR6 P50406 7/20 0.51
HTR2A P28223 7/20 0.44
HTR2C P28335 5/20 0.44
HTR2B P41595 5/20 0.44
HTR7 P34969 5/20 0.41
HTR1D P28221 4/20 0.41
HTR1B P28222 4/20 0.41
HTR1E P28566 3/20 0.41
HTR5A P47898 3/20 0.41
HTR3E A5X5Y0 2/20 0.41
HTR3B O95264 2/20 0.41
HTR1F P30939 2/20 0.41
HTR3A P46098 2/20 0.41
HTR4 Q13639 2/20 0.41
HTR3D Q70Z44 2/20 0.41
HTR3C Q8WXA8 2/20 0.41
MTNR1A P48039 2/20 0.40
MTNR1B P49286 2/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL31440956 0.90 HTR1A (0.64) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25423705 0.89 HTR1A (0.74) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL30916159 0.87 HTR1A (1.00) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25747526 0.87 HTR1A (1.00) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL30483740 0.86 HTR1A (0.56) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25424142 0.86 HTR1A (0.56) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL32669284 0.84 HTR1A (0.68) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25423844 0.84 GPR84 (0.56) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25748550 0.84 HTR1A (0.79) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL30483770 0.82 HTR1A (0.52) HTR1AHTR6HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034119-A1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-02-05 US disclosed
US-20250101038-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-03-27 US disclosed
EP-4452937-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 EP disclosed
CN-118715204-A Compounds of formula (I) 普赛洛私人有限公司 2024-09-27 CN disclosed
WO-2023115166-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 WO disclosed
WO-2023115166-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034119-A1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS HTR4, OPRM1, HTR7 HTR1A 4/4885HTR6 8/4885HTR2A 12/4885
US-20250101038-A1 COMPOUNDS NLN, SLC18A2, PYGB HTR1A 185/4885HTR6 54/4885HTR2A 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.